Dowpharma sells UK businesses

Dow Chemical has sold its Dowpharma Small Molecules business, along with its Mirfield, West Yorkshire and Cambridge sites, to the European subsidiary of India-based Dr Reddy’s Laboratories.



While the financial details of the contract were not disclosed, the sale includes associated product and process technology, intellectual property and trademarks.



The ownership of the Mirfield and Cambridge facilities will also be transferred to Dr Reddy’s, and employees directly related to the Dowpharma business at the sites will also join the new owners.



The Dowpharma businesses in the US, as well as the Pfenex Expression Technology, are not part of the agreement. Dr Reddy’s, however, does have a non-exclusive license to the Pfenex Expression Technology to support existing biocatalysis development.



Peter Davies, president of Dow’s Designed Polymers and Latex business, said: ‘Dr Reddy’s core operations and capabilities are strongly aligned with the specialty chiral and biocatalysis custom manufacturing business, so it is well equipped to help these businesses reach their full potential. Our priority now is working closely with Dr Reddy’s to continue to ensure a seamless transition for our customers.’